Core Viewpoint - LakeShore Biopharma Co., Ltd has announced a merger agreement with Oceanpine Skyline Inc., implying an equity value of approximately US$37 million for the company [1]. Merger Details - The merger will involve the cancellation of each ordinary share of LakeShore Biopharma in exchange for US$0.90 in cash per share [2]. - The merger consideration represents a premium of approximately 15.4% to the closing price of the shares on August 15, 2025, and a premium of approximately 16.6% to the average closing price during the last 15 trading days prior to that date [3]. - Certain shareholders, known as Rollover Shareholders, have agreed to cancel their shares for newly issued shares of Parent as part of a support agreement [4]. Funding and Approval - The merger will be funded through a combination of cash contributions from Oceanpine Capital Inc. and equity rollover by the Rollover Shareholders [5]. - The board of directors has unanimously approved the merger agreement and will recommend that shareholders vote in favor of it [6]. - The merger is expected to close in the first quarter of 2026, pending approval from at least two-thirds of the votes cast by shareholders [7]. Advisory and Documentation - Kroll, LLC is serving as the financial advisor to the Special Committee, while various law firms are providing legal counsel [8]. - The company will file a current report with the U.S. Securities and Exchange Commission (SEC) regarding the merger, including the merger agreement [10]. - A proxy statement will be prepared and mailed to shareholders, along with a Schedule 13E-3 Transaction Statement [11].

Core Viewpoint - LakeShore Biopharma has formed a Special Committee to evaluate a revised preliminary non-binding acquisition proposal and has engaged financial and legal advisors for this process [1][2]. Company Overview - LakeShore Biopharma, formerly known as YS Biopharma, is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer [3]. - The company utilizes a proprietary PIKA immunomodulating technology platform and targets diseases such as Rabies, Hepatitis B, and Influenza [3]. - LakeShore Biopharma operates in China, Singapore, and the Philippines, led by a management team with extensive local and global biopharmaceutical experience [3].